Updated June 2026. This article was originally published in 2024 and has been refreshed to reflect the 2026 MedTech and BioTech landscape.
Navigating the Evolving Landscape of Medtech: Trends Shaping the Future
The field of medical technology, or medtech, is constantly evolving as innovations and advancements are made not only in the field itself but across science. From artificial intelligence to data security, many factors are shaping the future direction of medtech. In this article we explore the key trends expected to have a major impact on the industry through 2026 and into the foreseeable future.
Medtech requires some of our smartest brains, many of whom are drawn not from the medical profession as we know it but from pure science and applied engineering. To attract the finest people around the world, the industry must offer excellent conditions and retain talent in a rapidly changing environment.
The major centre for, and funder of, global medtech remains the USA, so conditions there shape the availability of capital for the sector relative to others. Through 2025 and into 2026, the cost of capital stayed elevated relative to the cheap-money decade, and pricing pressure from US drug-pricing reform (including the Inflation Reduction Act) continues to flow through to how big pharma values the medtechs it ultimately commercialises. When the most lucrative first market is repriced, early-stage funding recalibrates with it, as investors reset the sale and royalty multiples they expect.
The impact of finance
The healthcare industry keeps evolving on the back of technological advances, regulatory change, and shifting care paradigms, and over the last twenty years investment has moved in cycles. The medtech industry is well positioned for continued growth against an aging world population with large unmet needs: the med-device market was forecast at roughly USD 595 billion in 2024, growing at about a 6.1% compound annual rate from 2022 to 2030, with cardiovascular, orthopedic, neurological, urological, and diabetes among the largest profit pools.[1] That trajectory still holds in 2026, and the sector retains a clear and growing demand for finance.
Any new project seeking funding in 2026 must clearly differentiate itself from current competitors, and especially from those who went before and failed. With so many technologies emerging in the medtech space there is bound to be overlap, so companies must articulate their value proposition sharply to secure capital. What has changed is the bar: investors now expect early pilots with measurable clinical, workflow, or economic impact, clean integration into existing infrastructure, and a credible regulatory and security story as prerequisites rather than as differentiators.
Bridging the gap between business and capital
From concept to investor-ready
We ensure your project resonates with the market, delivering the confidence investors need to move forward.
The significance of an Information Memorandum in medtech investments
In the dynamic landscape of medtech investments, understanding what an information memorandum is is crucial. This document presents a comprehensive view of your medtech venture to potential investors, enabling informed decisions and securing the financial backing essential for innovation and growth. With detailed market analysis, financial forecasts, and strategic objectives, an information memorandum ensures transparency and builds confidence among stakeholders, which matters all the more in a fast-moving field like medtech.
The funding challenge in 2026
Funding in 2026 is more disciplined than it was in 2024, but it is still very much open for the right stories. Venture capitalists are highly selective on medtech valuations, and fundraising is hard work for early-stage companies as funds prioritise their existing portfolio, risk mitigation, and nearer-term returns. At Projects RH we have worked with a company that needed to raise capital locked up in a development phase for four years, which is commonly not aligned with the investor’s risk profile. Potential investors increasingly want more clinical data, even when it sits outside the formal FDA accreditation process. Our clients have to differentiate themselves and articulate a unique value proposition to secure funding.
Intellectual property, the great differentiator
As Projects RH works with medtechs and biotechs it is clear that one of their greatest assets is their intellectual property. The rise of open-source technology challenges anyone relying on differentiation alone as their moat, so patents and trademarks become increasingly important to defend.
The final proof
Most parties in the sector plan an exit once the technology is proven. Strikingly, medtech resembles the resources sector, with a hierarchy of exploration, development, and commercialization companies, so the market between them is critical. It is a world of farm-in, acquisition, or IPO. The final proof only arrives when a product earns market acceptability, and here lies the clear difference with resources: if you produce gold it sells at the market price, but if you produce a better cure for the common cold it still has to achieve market acceptance.
Bridging the gap between business and capital
From concept to investor-ready
We ensure your project resonates with the market, delivering the confidence investors need to move forward.
Outsourcing and where things get made
As the medtech industry grows more complex, many companies turn to outsourcing to increase efficiency and reduce cost. By outsourcing parts of product development and manufacturing, medtech companies can focus on their core competencies and reach market faster, while accessing specialised expertise and resources they could not build alone.
The cost of operations in the US remains high, and in the post-COVID world many markets want local or near-shore manufacturing. At Projects RH we see manufacturing continuing in Mexico for the USMCA and LatAm markets; China, Taiwan, and Thailand for Asia; and the Middle East and Central Europe for European and North African markets. We also see the growing involvement of Indian manufacturing.
The AI factor in 2026
Artificial intelligence has moved from pilots to infrastructure. In 2026, hospitals are deploying large-language-model clinical copilots and scribe tools for documentation, coding, and decision support, while deep-learning diagnostics in imaging and cardiology now sit natively inside PACS and EHR workflows rather than as standalone viewers. AI is also used across real-world-evidence generation, trial design, and regulatory submissions, analysing multi-modal datasets that span EHR, imaging, and genomics. For medtech companies this is the chance to enhance patient outcomes, optimise resource use, and change how care is delivered, provided the data governance holds up.
We continue to see pharmacy resellers (drug stores and chemists) move into telehealth, where a practitioner seeing a patient remotely has access to online data and diagnostic tools, including laboratory and imaging results. The computer-aided recommender prepares suggestions for the online doctor that professionals are increasingly reluctant to reject. We have already seen AI in medical imaging analyse scans and detect abnormalities with accuracy that rivals or exceeds human radiologists, which raises real ethical and social questions even as it enables a more personalised approach to medicine.
Continuous monitoring, wearables, and robotics
Remote monitoring and wearables have shifted from step counters to continuous, reimbursed data streams. Cardiac patches, continuous glucose monitors, connected inhalers, and emerging ear-ables feed longitudinal data into virtual-care platforms, while home blood diagnostics and at-home cancer screening gain coverage and physician adoption. Founders are now asked how device data integrates into clinical workflows and the revenue cycle, not just into an app. Medical robotics, meanwhile, is in a scale-up phase: surgical robotics is expanding into ambulatory surgery centres and new soft-tissue indications, competing on haptics, smaller footprint, AI-guided workflows, and telesurgery enabled by faster connectivity and edge computing.
The new gold: data, security, and regulation
One of the greatest benefits of modern medtech is the data its application creates, and the predictive ability to protect individuals using individual and population-level data, which offers huge risk-mitigation potential. The corresponding challenge is protecting people and communities from that data becoming a target for cyber threats, which is pushing more devices toward secure remote monitoring and software-as-a-service models with feedback to the user.
By 2026, data security and regulation sit at the front of term sheets. The FDA’s evolving framework for AI and machine-learning devices, real-time algorithm change control, and stricter post-market surveillance, combined with the EU Medical Device Regulation and the high-risk requirements of the EU AI Act, are forcing companies to tell a clear validation, monitoring, and cyber-resilience story. Investors now probe software bills of materials, penetration-testing practices, and privacy-preserving analytics before they commit.
We thank the teams at Neva Healthcare, led by John Stephens, and at Ad Solis / AdAlta, led by Tim Oldham, for keeping us focused on the markets for MedTech and BioTech.
[1] Dykeman, D.J., et al; “Six Trends Reshaping Medtech In 2024“, Medical Product Outsourcing (MPO-Mag), 1 April 2024, cited here as the baseline market forecast.
